Murphy Nicole (Head of Pharm Ops and Tech) bought 3 shares of BIIB at $195.04 on 2026-02-12.
Murphy Nicole's purchase of 3 shares represents a net change of +0.0% to her existing holdings of 19,611 shares, reflecting a minimal transaction in absolute and relative terms. The stock has appreciated 19.0% over the past 30 days and 16.5% over 90 days, trading near its 52-week high at $195.62 (down only 2.8% from the 52-week peak of $201.18). BIOGEN's fundamentals show stable operational metrics with $2.5B quarterly revenue and net income of $466.5M, though annual revenue growth is modest at +2.2%. The transaction's immaterial scale and negligible portfolio impact provide limited signaling value regarding insider conviction or strategic positioning.